

ROUND 1

Dear editors from World Journal Of Immunology, BPG

Regarding the manuscript 6766 entitled Historical evolution, overview, and therapeutic manipulation of co-stimulatory molecules.

We appreciate the observations of the reviewers and the suggested modifications have been made. Here by we described the corrections made to the manuscript in

Observations:

Reviewer #1:

Scientific Quality: Grade C (Good)

Language Quality: Grade C (A great deal of language polishing)

Conclusion: Major revision

Specific Comments to Authors: The article entitled “Historical evolution, overview, and therapeutic manipulation of co-stimulatory molecules” by Soto et al. provides a brief overview on different aspects of co-stimulatory molecules. These aspects have been neatly divided into subsections. However, the information provided in each of these sections appears to be incomplete. The abstract and introduction are poorly written and the Core tip appears to be incomplete. While there are only few grammatical errors, the writing style throughout the article lacks coherence and needs rewriting. Specifically, there many sentences which can be divided into two or more different sentences instead of being separated by a semi-colon. Instead of merely mentioning the Figures and Tables in the text, it would more appropriate to briefly describe each of them in the body of the article. The figure legends also need re-writing. In conclusion, the article cannot be accepted in the present form and needs a great deal of polishing both in terms of language and scientific content.

Response:

We appreciate the valuable observations made to the manuscript.

Adequations to the manuscript were made to fulfill the indicated observations.

- a) Abstract was restructured and rewritten for better comprehension.
- b) Introduction was restructured and rewritten for better comprehension.
- c) Content in the pointed sections was broadened.
- d) Figures and tables legends were extended and explained in detail.
- e) The manuscript has been revised for language polishing and editing by English native speaker certified service Filipodia as suggested by BPG editorial.

Observations:

Reviewer #2:

Scientific Quality: Grade C (Good)

Language Quality: Grade B (Minor language polishing)

Conclusion: Major revision

Specific Comments to Authors: In the manuscript “Historical evolution, overview, and therapeutic manipulation of co-stimulatory molecules”, the authors introduce the brief history of co-stimulation molecules, the generalities of antigenic presentation and participation of co-stimulation molecules, activating and inhibitory signals, families of co-stimulatory molecules, co-stimulation molecules and their study in diseases and therapeutic application of co-stimulatory or co-inhibitory molecules. The knowledge the authors introduced is relatively familiar for the readers. I suggest the authors would give more interesting and explorative knowledge, such as what is the most important research area for the current basic research, what is the main problem/expectation in current clinical study, what is the prospective area in future.

Response:

Adequations to manuscript were made to fulfill the indicated observations.

a) The authors considered relevant the observations regarding the limitations and challenges of these therapies. A paragraph pointing the main challenges of biological therapies was added.

On behalf

Henry Velázquez Soto

ROUND 1

Authors suggestions have been taken into consideration and modifications have been made. “I suggest the authors cite more papers on corneal transplantation using CTLA4Ig and ICOSIg gene therapy from Uwe Pleyer/ Thomas Ritter (Germany, Berlin, Charite)” Although we find the suggestions very valuable, we consider this topic could be addressed in a different review since the scope of our manuscript is focused on monoclonal antibodies/ recombinant proteins targeting costimulatory molecules in different diseases.

As commented in previous mails, we have no access to replying to the reviewers. Hereby we provide our humble response : “I suggest the authors cite more papers on corneal transplantation using CTLA4Ig and ICOSIg gene therapy from Uwe Pleyer/ Thomas Ritter (Germany, Berlin, Charite)” Although we find the suggestions very valuable, we consider this topic could be addressed in a different review since the scope of our manuscript is focused on monoclonal antibodies/ recombinant proteins targeting costimulatory molecules in different diseases.